Navigation Links
FDA Approves Dendreon's Los Angeles Cancer Immunotherapy Manufacturing Facility
Date:6/29/2011

SEATTLE, June 29, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) approved its Los Angeles cancer immunotherapy manufacturing facility, allowing the company to continue to increase the availability of PROVENGE® (sipuleucel-T) across the U.S. to help meet the needs of patients with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.  

The Los Angeles facility includes 36 workstations, and Dendreon will bring these new workstations online in a staged approach. With this FDA approval and the fully approved New Jersey facility, Dendreon now has total of 84 workstations available to manufacture PROVENGE. Dendreon expects to continue to provide additional capacity through the anticipated licensure mid-year of one other manufacturing facility in the United States.  In April, Dendreon filed a post-approval supplement for its third facility in Atlanta, for which there is an FDA action date of August 28, 2011.

PROVENGE is designed to induce an immune response against prostatic acid phosphatase (PAP), an antigen expressed in most prostate cancers, and is the first in a new therapeutic class of drugs known as autologous cellular immunotherapies.

"As the foundation of care, PROVENGE is an important treatment option for men with metastatic castrate resistant prostate cancer," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "The FDA approval of the Los Angeles facility will enhance our ability to provide PROVENGE to the many patients across the country who may benefit from it."  

In anticipation of the availability of the additional workstations, Dendreon expects to have approximately 225 active infusing sites by the end of the second quarter and approximately 500 by the end
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Approves New Device to Treat Brain Aneurysms
2. European Commission Approves DuPont Tender Offer to Acquire Danisco
3. New York State Approves the Quest Diagnostics ColoVantage™ Colorectal Cancer Blood Test
4. European Medicines Agency Approves Pediatric Investigational Plan for Pixuvri
5. FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy
6. European Union Approves Maize with Herculex® I/Herculex® RW and Herculex® RW/ Herculex® I/Roundup Ready® Corn 2 Trait Stacks for Import, Food, Feed & Processing
7. FDA Approves First-of-Its-Kind HIV Test Which Can Detect HIV Days Earlier Than Current U.S. Tests
8. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
9. FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS)
10. European Union Approves Corn Stack with Herculex RW and Roundup Ready 2 Traits for Food, Feed, Import and Processing
11. EU Committee Approves New Food Applications for Marteks lifesDHA(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... and COLLEGE STATION, Texas , July 28, 2014 ... theatlashotel.com will be a 177-key, 4-star boutique hotel in the ... Bryan , Texas.  Photo - http://photos.prnewswire.com/prnh/20140725/130455 ... As the first hotel within ATLAS , ... a mixture of standard rooms and suites, a sleek restaurant and ...
(Date:7/25/2014)... NY (PRWEB) July 26, 2014 ... Review, H2, 2014" provides data on the Ischemic ... report provides elemental information and data relating to ... Stroke. , View full global Ischemic Stroke Research ... includes an overview of the trial numbers and ...
(Date:7/25/2014)... 25, 2014 Research and Markets ... Metabolomics Market 2014-2018" report to their offering. ... Metabolomics or Metabonomics is the scientific study ... a new experimental technique that is being widely ... Metabolites are small molecules that are present in ...
(Date:7/25/2014)... 2014 Lawrence Livermore scientists Charles Westbrook ... list of " The World's Most Influential Scientific Minds ... 3,000 researchers who were identified by analyzing citation data ... published the highest-impact work (2002-2012 and 2012-2013). The two ... combustion modeling . , "This recognition is a great ...
Breaking Biology Technology:Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 3Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 4Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4
... 2009 Senomyx, Inc. (Nasdaq: SNMX ), ... discover and develop novel flavor ingredients for the food, ... SA has selected a new flavor ingredient, which was ... for development activities and evaluation of commercial potential in ...
... -- American Oriental,Bioengineering, Inc. (NYSE: AOB ), ... manufacture and commercialization of,a broad range of prescription and ... Company,s participation in the following conferences: , , ... May 6-8 at the Ritz Carlton in, ...
... Breakthrough biotechnology research is providing new applications ... and diabetes, two leading health concerns among consumers. ... Advana Science, www.advanascience.com , will ... this dynamic consumer healthy category at VitaFoods International ...
Cached Biology Technology:SENOMYX ANNOUNCES NESTLE'S SELECTION OF A NEW FLAVOR INGREDIENT FOR EVALUATION OF COMMERCIAL POTENTIAL 2SENOMYX ANNOUNCES NESTLE'S SELECTION OF A NEW FLAVOR INGREDIENT FOR EVALUATION OF COMMERCIAL POTENTIAL 3Industry Expert Reveals Cutting Edge Biotechnology Science for Nutraceutical and Functional Food Applications 2
(Date:7/28/2014)... and other forms of dementia, but the research community ... of Washington bioengineers have a designed a peptide structure ... normal proteins into a state that,s linked to widespread ... diabetes and Lou Gehrig,s disease. The synthetic molecule blocks ... into an abnormally folded form by targeting a toxic ...
(Date:7/28/2014)... that 73 percent of adult survivors of childhood cancer ... and related health problems by failing to follow a ... of the journal Cancer . , Almost 32 ... in the study had metabolic syndrome, an umbrella term ... obesity, elevated triglyceride and other abnormalities that often occur ...
(Date:7/28/2014)... Research and Markets has announced the addition ... report to their offering. ... biological data. These systems capture biological traits such as ... hand measurements from the subject and compare the data ... of a biometrics system is to identify and verify ...
Breaking Biology News(10 mins):New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3Biometrics Market in Latin America 2014-2018 2
... on Contact Metallic copper surfaces kill microbes ... in the February 2011 issue of the journal ... in minutes, by causing massive membrane damage after about ... Grass of the University of Nebraska, Lincoln. This is ...
... Qqest and M2SYS Technology, a global biometrics research and ... to offer TimeForce time and attendance customers the added ... their PC. M2SYS, RightPunch(TM) solution enables the ... interface with Qqest,s TimeForce time and attendance system, providing ...
... cancer, and development of new cancer therapeutics, has focused ... of focus is the life and death of a ... cell death, is a fundamental process of cells including ... involve many different proteins and their interactions with each ...
Cached Biology News:Tips from the journals of the American Society for Microbiology 2Tips from the journals of the American Society for Microbiology 3Tips from the journals of the American Society for Microbiology 4Tips from the journals of the American Society for Microbiology 5Tips from the journals of the American Society for Microbiology 6Tips from the journals of the American Society for Microbiology 7Qqest Teams Up With M2SYS to Add Biometric Technology at the Desktop to TimeForce Time and Attendance System 2Qqest Teams Up With M2SYS to Add Biometric Technology at the Desktop to TimeForce Time and Attendance System 3Designing new molecular tools to study the life and death of a cancer cell 2Designing new molecular tools to study the life and death of a cancer cell 3Designing new molecular tools to study the life and death of a cancer cell 4
iNOS/NOS Type II Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 150 µg Consult technical datasheet for details....
... The Bio-Plex suspension array system, 100-240 ... technology) for simultaneous quantitative analysis of up ... single microplate well. The suspension array is ... sets, each of which may be conjugated ...
... fluidics (HTF) system, 100-240 V, is an ... system that automates delivery of up to ... Bio-Plex array reader. The HTF system automatically ... sheath container to constantly maintain a reservoir ...
Cell Culture Flask, 75 cm, nontreated polystyrene...
Biology Products: